Evidence map›Paper›PMID 42696401›Full record

ReviewPediatric dermatology2026

Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa.

Alberto Pappalardo, Edward Eid, Rebecca C Olsen, Savannah E Bush, Lawrence F Eichenfield, Maria Gnarra Buethe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alberto PappalardoDepartment of Dermatology, Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-8949-2552
Edward EidDepartment of Dermatology, Stanford University School of Medicine, Palo Alto, California, USA.ORCID https://orcid.org/0000-0002-9355-2474
Rebecca C OlsenNorthwest Medical Center Transitional Year Residency Program, Tucson, Arizona, USA.ORCID https://orcid.org/0000-0001-5328-3284
Savannah E BushTulane University School of Medicine, New Orleans, Louisiana, USA.
Lawrence F EichenfieldDepartments of Dermatology, and Pediatrics, University of California, San Diego, California, USA.ORCID https://orcid.org/0000-0002-2760-0474
Maria Gnarra BuetheDepartment of Dermatology, University of California Irvine, Irvine, California, USA.ORCID https://orcid.org/0000-0002-3872-1415

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dystrophic epidermolysis bullosa (DEB) and junctional EB (JEB) are severe, bullous genodermatoses induced by mutations of genes encoding structural skin proteins that disrupt epidermal adhesion. Until recently, treatment was limited to symptomatic care. Since 2022, three therapies - birch triterpenes gel (Filsuvez), beremagene geperpavec-svdt (B-VEC, Vyjuvek), and prademagene zamikeracel (pz-cel, Zevaskyn) - have received regulatory approval, representing the first specific interventions for epidermolysis bullosa. Herein, we provide an overview on their mechanisms of action, efficacy, safety, and clinical implications.

Indexed as

Epidermolysis Bullosa DystrophicaEpidermolysis Bullosa, JunctionalGenetic TherapyHumanscell therapyepidermolysis bullosagene therapyprecision medicinewound healing

Identifiers

PMID42696401
PMCPMC13544483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.